Skip to main content
Log in

Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The influence of food on release of drug from a modified release capsule of bromocriptine 5 mg (Parlodel SRO) and a conventional formulation of bromocriptine 5 mg has been studied in 8 healthy male volunteers.

Both formulations produced objective and subjective effects, such as orthostatic reactions, nausea, dizziness, vomiting and nasal congestion. The modified release capsule caused fewer side-effects than the normal capsule. Both formulations had less cardiovascular effect in the fed than in the fasting state.

There was no significant difference between the normal and the modified release capsules taken fasting or after a meal in terms of the AUC extrapolated to infinity. The relative bioavailability of the 5 mg modified release capsule was 84.6% of the normal capsule under fasting conditions and 107.5% after food. In contrast to the virtually unchanged extent of absorption, the rate of absorption was markedly affected by food, especially from the conventional capsule. The mean time of 50% absorption increased from 1.06 h (fasting) to 3.2 h (fed), whereas for the modified release capsule food mainly resulted in an increased lag time of absorption.

The almost instantaneous dissolution of bromocriptine from the normal capsule in vitro (both in HCl and fasting human gastric juice) and the delay of absorption after a meal in vivo suggest that the rate limiting step in absorption of the normal capsules is delivery of released drug from the stomach to the small intestine, which is delayed by food.

Both the modified release 5-mg capsule and the normal 5-mg capsule showed extended suppression of prolaction over 36 h, in all subjects, both fasted and after a meal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Thorner MO, Flueckiger E, Calne DB (1980) Bromocriptine. A clinical and pharmacological review. Raven Press, New York, pp 55–99

    Google Scholar 

  2. Schran HF, Bhuta SI, Schwarz HJ, Thorner MO (1980) The pharmacokinetics of Bromocriptine in man. In: Goldstein M, Calne DB, Lieberman A, Thorner MO (1980) Ergot compounds and brain function: Neuroendocrine and neuropsychiatrics aspects. Raven Press, New York, pp 125–139

    Google Scholar 

  3. Fimmel CJ, Etienne A, Cilluffo T, v Ritter C, Gasser T, Rey JP, Caradonna-Moscatelli P, Sabbatini F, Pace F, Buehler HW, Bauerfeind P, Blum AL (1985) Long-term ambulatory gastric pH monitoring: Validation of a new method and effect of H2-antagonists. Gastroenterology 88: 1842–1851

    Google Scholar 

  4. Mojaverian P, Ferguson RK, Vlasses PH, Rocci ML, Oren A, Fix JA, Caldwell LJ, Gardner C (1985) Estimation of gastric residence time of the Heidelberg Capsule in humans: Effect of varying food composition. Gastroenterology 88: 392–397

    Google Scholar 

  5. Melander A (1978) Influence of food on the bioavailability of drugs. Clin Pharmacokinet 3: 337–351

    Google Scholar 

  6. Skelly JP (1986) Issues and controversies involving controlled-release drug product studies. Pharmacy Int 1986: 7: 280–286

    Google Scholar 

  7. Woodhouse NJY, Niles N, McDonald D, McCorkell S (1985) Prolactin levels in pregnancy, comparisons of normal subjects with patients having micro or macro adenomas after early bromocriptine withdrawal. Horm Res 21: 1–9

    Google Scholar 

  8. Rosenthaler J, Munzer H, Voges R (1983) Immunoassay of bromocriptine and specificity of antibody: Criteria for choice of antiserum and marker compound. In: Reid E, Leppard JP (eds) Drug metabolite isolation and determination. Plenum Publishing, New York, pp 215–223

    Google Scholar 

  9. Sheiner LB (1981) Program for the extended least squares fit to individual pharmacokinetic data. User's manual, February 1981. Division of Clinical Pharmacology, University of California, San Francisco, USA

    Google Scholar 

  10. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York Basle

    Google Scholar 

  11. RS/1 User's Guide (1983) BBN Research Systems, Bold Beranek and Newman, Cambridge, Mass, USA

    Google Scholar 

  12. Davis SS, Hardy JG, Fara JW (1986) Transit of pharmaceutical dosage forms through the small intestine. Gut 27: 886–892

    Google Scholar 

  13. Meyer JH, Mayer EA, Jehn D, Gu Y, Fink AS, Fried M (1986) Gastric processing and emptying of fat. Gastroenterology 90: 1176–1187

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drewe, J., Mazer, N., Abisch, E. et al. Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 35, 535–541 (1988). https://doi.org/10.1007/BF00558250

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00558250

Key words

Navigation